News

Urine drug testing is a fixture in both clinical medicine and workplace compliance. It’s a tool deployed to manage risk—screening for substance use before surgery, hiring, or as part of ongoing employment. But in the rapid velocity of policy updates and shifting legal frameworks—especially around medical cannabis—confusion compounds. Patients, employers, and even clinicians often find […]

Drug testing in medical settings is not new—workplace safety programs, pain management clinics, and addiction treatment centers have relied on biological sampling for decades to triage patient needs and manage risk. But in the rapidly evolving landscape of medical cannabis, urine drug testing has taken on a new velocity and visibility. For both patients and […]

Drug testing didn’t start as a mainstream business risk, but its currency has only compounded over the past decade. Today, employers are scrutinized for compliance lapses, courts demand forensic accuracy, and healthcare providers face complex triage when substance use is suspected. The friction is real: One missed detail in a test can evaporate legal protections […]

Medical cannabis programs have evolved at a velocity that few in healthcare anticipated. Once restricted to a handful of jurisdictions, these programs now touch millions of patients in over 40 U.S. states, as well as dozens of countries abroad. This rapid expansion amplifies not only patient access but also the compounding responsibility of compliance—for both […]

Medical cannabis programs have proliferated at a striking velocity over the past decade, moving from fringe policy experiments to mainstream components of national healthcare systems. Canada, Germany, Israel, and over half of U.S. states now operate some form of regulated medical cannabis access. But in many cases, program expansion has outpaced the creation of robust […]

Medical cannabis programs have proliferated at a velocity few predicted a decade ago—38 U.S. states as of 2024, millions of registered patients, and a regulatory landscape that shifts almost quarterly. But for all the compounding interest and capital, the core value proposition remains unchanged: deliver therapeutic benefit without introducing new risks. This is what leads […]

Montana’s medical cannabis program is navigating a period of rapid growth, compounding both opportunity and complexity for patients and providers alike. The regulatory velocity is high—new requirements, shifting forms, and evolving compliance mandates are creating friction at every stage of the process. But in many cases, what evaporates quickest is clarity: Who owns which piece […]

Medical cannabis has moved decisively from the margins to the mainstream of healthcare practice. According to the 2023 National Academies of Sciences review, over 5 million Americans now use cannabis through state-sanctioned medical programs—a figure that continues to accelerate as regulatory friction lessens and clinical interest compounds. But with this velocity comes a new set […]

Patient compliance is the silent engine that determines whether medical cannabis programs deliver on their promises—or stall under the weight of compounding operational, legal, and reputational risks. In this context, “compliance” doesn’t simply mean ticking boxes; it is the act of adhering to a complex amalgamation of guidelines, documentation protocols, dosage regimens, and ongoing communication […]

The past decade has seen a compounding surge in the use of medical cannabis, with patient registries swelling and dispensaries multiplying at a velocity few policymakers anticipated. As the landscape shifts, one concern consistently rises to the top: public safety. It’s a scenario that’s becoming more and more common—legislators, community leaders, and families triage news […]